Carregant...
Cardiovascular toxicity following anti-angiogenic therapy in persons over age 65 with advanced renal cell carcinoma
BACKGROUND: Sunitinib and sorafenib are oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of patients with renal cell carcinoma (RCC) in 2005-2006. We conducted a population-based observational cohort study on the cardiovascular risk of...
Guardat en:
| Publicat a: | Cancer |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4602387/ https://ncbi.nlm.nih.gov/pubmed/26439451 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29728 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|